2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 68

A Genome-Wide Association Study Identifies rs116199914 As an Intergenic Variant Associated with Carotid Intima-Media Thickness in Spanish Patients with Rheumatoid Arthritis
Abstract Number: 1871

A High Cardiovascular Biomarker Panel Risk Score Is Associated with Increased 10-Year Risk of Cardiovascular Events and Death in SLE
Abstract Number: 728

A Higher Activity Index at Initial Renal Biopsy Is Associated with Rapid Progression to Renal Failure in Patients with Refractory Lupus Nephritis
Abstract Number: 61

A Human ACPA Monoclonal Antibody Is Preferably Localized at Inflammatory Gingival Tissue and Activates Osteoclastogenensis in Porphyromonas Gingivalis Infected SKG Mouse
Abstract Number: 2341

A Link between Quality of Patient–Rheumatologist Communication and Patient Healthcare Needs in Psoriatic Arthritis: An Online Survey of US-Based Patients and Rheumatologists
Abstract Number: 2762

A Longer or Bilateral Temporal Artery Biopsy (TAB) Is More Likely to Yield a Positive Result for Giant Cell Arteritis (GCA) in the Veterans Health Administration (VHA) Database Cohort
Abstract Number: 1359

A Machine Learning Approach to Knee OA Phenotyping: The Johnston County Osteoarthritis Project
Abstract Number: 919

A Machine Learning Classifier for Assigning Individual Patients with Systemic Sclerosis to Intrinsic Molecular Subsets
Abstract Number: 983

A MAPK Activated Kinase 2 Inhibitor Attenuates Inflammatory and Destructive Arthritis in Human Ex Vivo Models
Abstract Number: 2146

A Meta-Analysis of the Prevalence and Risk Factors for Retinal Toxicity in Rheumatologic Patients on Hydroxychloroquine Therapy
Abstract Number: 2844

A Mixed-Methods Feasibility Study Exploring the Cultural Adaptation of Walk with Ease to the United Kingdom
Abstract Number: 1981

A Molecular Bayesian Network for Rheumatoid Arthritis Reveals Multiple Candidate Key Regulators for Disease Severity
Abstract Number: 2504

A More Time Under Remission Impacts in a Better Health-Related Quality of Life in Rheumatoid Arthritis Mestizo Population
Abstract Number: 2756

A Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice in Treatmet with Tocilizumab Compared with Giacta Trial
Abstract Number: 2528

A Multicenter Study Assessing the Efficacy and Safety of Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: Preliminary Interim Data from the Open-Label Treatment Period

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].